Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Invest New Drugs. 2010 Jan 15;29(3):473–480. doi: 10.1007/s10637-009-9381-y

Table 2.

Dose escalation scheme. The starting dose level for all cohorts was dose level 1. Bold indicates the MTD, when determined. In cohort A, one of the patients experiencing DLT did not complete cycle 1 and was replaced

Cohort Dose
level
Dose (mg/m2)
No. of
patients
DLTs
17-AAG Gemcitabine Cisplatin
A 1 154 750 40 6 0
2 154 1,000 40 3 3 (1)
B 0 154 750 40 3 1
1 231 750 40 3 2
C 1 154 750 6 1
2 231 750 3 2
D 0 154 30 3 0
1 154 40 3 2
E 1 300 750 20 3 2